Benjamin Ehst News Today

- Two posters will present data across secondary efficacy outcomes, quality of life and tolerability scores of tapinarof cream 1% once daily - Dermavant Sciences, a clinical-stage biopharmaceutical

Evelo Biosciences, Inc.: Evelo Biosciences Reports New Positive Confirmatory Data from Phase 1b Trial of EDP1815 in Atopic Dermatitis physician-reported outcomes - -Improvements in patient-reported outcomes in DLQI and POEM, including itch- -EASI50 benchmark reached in 44% of patients treated with EDP1815 compared to 0% in placebo group at day 70- -Phase 2 atopic dermatitis trial initiation in 3Q 2021- -Management to host conference call at 8:30 a.m. ET today with Dr. Benjamin Ehst- CAMBRIDGE,...